• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ironwood Pharmaceuti (NQ: IRWD )

    4.690 -0.070 (-1.47%)
    Streaming Delayed Price Updated: 3:49 PM EDT, Aug 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Ironwood Pharmaceuti

    < Previous 1 2 3 Next >
    Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals Reports First Quarter 2024 Results
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
    Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... 
    Via Newsfile
    Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
    From Ironwood Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.